Summary of Research: Ten-Year Safety and Clinical Benefit from Open-Label Etanercept Treatment in Children and Young Adults with Juvenile Idiopathic Arthritis

Jelena Vojinović; Ivan Foeldvari; Joke Dehoorne; Violeta Panaviene; Gordana Susic; Gerd Horneff; Valda Stanevica; Katarzyna Kobusinska; Zbigniew Zuber; Bogna Dobrzyniecka; Tadej Avcin; Cecilia Borlenghi; Edmund Arthur; Chuanbo Zang; Vassilis Tsekouras; Bonnie Vlahos; Alberto Martini; Nicolino Ruperto; Paediatric Rheumatology International Trials Organisation (PRINTO)

doi:10.1007/s40744-024-00703-z

Summary of Research: Ten-Year Safety and Clinical Benefit from Open-Label Etanercept Treatment in Children and Young Adults with Juvenile Idiopathic Arthritis

Rheumatol Ther. 2024 Sep 12. doi: 10.1007/s40744-024-00703-z. Online ahead of print.

Authors

Jelena Vojinović¹, Ivan Foeldvari², Joke Dehoorne³, Violeta Panaviene^{4

5}, Gordana Susic⁶, Gerd Horneff⁷, Valda Stanevica⁸, Katarzyna Kobusinska⁹, Zbigniew Zuber¹⁰, Bogna Dobrzyniecka¹¹, Tadej Avcin¹², Cecilia Borlenghi¹³, Edmund Arthur¹⁴, Chuanbo Zang¹⁵, Vassilis Tsekouras¹⁶, Bonnie Vlahos¹⁵, Alberto Martini¹⁷, Nicolino Ruperto¹⁸; Paediatric Rheumatology International Trials Organisation (PRINTO)

Affiliations

¹ University of Niš, Niš, Serbia.
² Hamburg Centre for Pediatric Rheumatology, Hamburg, Germany.
³ Department of Pediatric Rheumatology, European Reference Network RITA, Ghent University Hospital, Ghent, Belgium.
⁴ Children's Hospital, Affiliate of Vilnius University Hospital Santaros Clinic, Vilnius, Lithuania.
⁵ Clinic of Children's Diseases, Vilnius University, Vilnius, Lithuania.
⁶ University Children's Hospital, Belgrade, Serbia.
⁷ Asklepios Clinic Sankt Augustin, Sankt Augustin, and University Hospital of Cologne, Cologne, Germany.
⁸ Riga Stradins University, Children's University Hospital, Riga, Latvia.
⁹ Provincial Children's Hospital J. Brudzińskiego, Bydgoszcz, Poland.
¹⁰ Andrzej Frycz Modrzewski Krakow University, Krakow, Poland.
¹¹ Szpital Specjalistyczny im. A. Falkiewicza, Szpital Specjalistyczny, Wroclaw, Poland.
¹² University Children's Hospital, University Medical Centre, Ljubljana, Slovenia.
¹³ Pfizer, Buenos Aires, Argentina.
¹⁴ Pfizer, Peapack, NJ, USA.
¹⁵ Pfizer, Collegeville, PA, USA.
¹⁶ Pfizer, Hellas (Cyprus Branch), Nicosia, Cyprus.
¹⁷ Università degli Studi di Genova, Genoa, Italy.
¹⁸ IRCCS Istituto Giannina Gaslini, UOC Gaslini Trial Centre/Servizio di Sperimentazioni Cliniche Pediatriche/PRINTO, Via Gaslini 5, 16147, Genoa, Italy. nicolaruperto@gaslini.org.

PMID: 39264536
DOI: 10.1007/s40744-024-00703-z

Abstract

This is a summary of the original article 'Ten-year safety and clinical benefit from open label etanercept treatment in children and young adults with juvenile idiopathic arthritis'. Juvenile idiopathic arthritis (JIA) usually appears before the age of 16. JIA causes pain, swelling, and stiffness in the joints. People with JIA receive treatment for several years until the disease goes into prolonged remission. Therefore, the long-term safety of these treatments is an important topic. Etanercept is a treatment for JIA, which acts on the body's immune system to reduce arthritis. This summary of research article describes safety and how well etanercept works in children with JIA taking it for up to 10 years.